3-Thio-1,2,4-triazoles, novel somatostatin sst2/sst5 agonists.
Novel 3-thio-1,2,4-triazoles have been obtained via a solution-phase parallel synthesis strategy, affording potent non-peptidic human somatostatin receptor subtypes 2 and 5 agonists.